Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1996 1
1999 2
2000 2
2001 2
2002 4
2003 3
2004 5
2005 6
2006 6
2007 10
2008 10
2009 8
2010 19
2011 22
2012 8
2013 4
2014 8
2015 9
2016 11
2017 12
2018 12
2019 21
2020 18
2021 7
2022 6
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

189 results

Results by year

Filters applied: . Clear all
Page 1
Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages.
Feurstein S, Trottier AM, Estrada-Merly N, Pozsgai M, McNeely K, Drazer MW, Ruhle B, Sadera K, Koppayi AL, Scott BL, Oran B, Nishihori T, Agrawal V, Saad A, Lindsley RC, Nakamura R, Kim S, Hu Z, Sobecks R, Spellman S, Saber W, Godley LA. Feurstein S, et al. Among authors: sobecks r. Blood. 2022 Dec 15;140(24):2533-2548. doi: 10.1182/blood.2022015790. Blood. 2022. PMID: 35969835 Free PMC article.
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.
Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim HJ, Mikesch JH, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine SM, Horowitz MM, Chen YB; BMT-CTN 1506/MORPHO Study Investigators. Levis MJ, et al. J Clin Oncol. 2024 May 20;42(15):1766-1775. doi: 10.1200/JCO.23.02474. Epub 2024 Mar 12. J Clin Oncol. 2024. PMID: 38471061 Clinical Trial.
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).
Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J. Bolaños-Meade J, et al. Among authors: sobecks r. Lancet Haematol. 2019 Mar;6(3):e132-e143. doi: 10.1016/S2352-3026(18)30221-7. Lancet Haematol. 2019. PMID: 30824040 Free PMC article. Clinical Trial.
Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation.
Pagliuca S, Gurnari C, Hercus C, Hergalant S, Hong S, Dhuyser A, D'Aveni M, Aarnink A, Rubio MT, Feugier P, Ferraro F, Carraway HE, Sobecks R, Hamilton BK, Majhail NS, Visconte V, Maciejewski JP. Pagliuca S, et al. Among authors: sobecks r. Nat Commun. 2023 May 31;14(1):3153. doi: 10.1038/s41467-023-38113-4. Nat Commun. 2023. PMID: 37258544 Free PMC article.
Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation.
Pagliuca S, Gurnari C, Hercus C, Hergalant S, Hong S, Dhuyser A, D'Aveni M, Aarnink A, Rubio MT, Feugier P, Ferraro F, Carraway HE, Sobecks R, Hamilton BK, Majhail NS, Visconte V, Maciejewski JP. Pagliuca S, et al. Among authors: sobecks r. Res Sq [Preprint]. 2023 Apr 5:rs.3.rs-2773498. doi: 10.21203/rs.3.rs-2773498/v1. Res Sq. 2023. PMID: 37066269 Free PMC article. Updated. Preprint.
Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease prevention.
Hamilton BK, Rybicki LA, Li H, Lucas T, Corrigan D, Kalaycio M, Sobecks R, Hanna R, Rotz SJ, Dean RM, Gerds AT, Jagadeesh D, Brunstein C, Sauter CS, Copelan EA, Majhail NS. Hamilton BK, et al. Among authors: sobecks r. Blood Adv. 2023 Aug 22;7(16):4505-4513. doi: 10.1182/bloodadvances.2023010310. Blood Adv. 2023. PMID: 37352262 Free PMC article. Clinical Trial.
Evaluation of pre-transplant risk assessments in allogeneic hematopoietic cell transplant.
Hegde PS, Rybicki L, Serafino S, Bernhard L, Corrigan D, Anwer F, Kalaycio M, Sobecks RM, Jagadeesh D, Hill BT, Dean RM, Khouri J, Winter AM, Pohlman B, Majhail NS, Hamilton BK. Hegde PS, et al. Among authors: sobecks rm. Bone Marrow Transplant. 2022 Jun;57(6):1031-1033. doi: 10.1038/s41409-022-01677-8. Epub 2022 Apr 15. Bone Marrow Transplant. 2022. PMID: 35428866 No abstract available.
Toxicity analysis of busulfan pharmacokinetic therapeutic dose monitoring.
Gaffney KJ, Urban TA, Lucena M, Anwer F, Dean RM, Gerds AT, Hamilton BK, Jagadeesh D, Kalaycio ME, Khouri J, Pohlman B, Sobecks R, Winter A, Rybicki L, Majhail NS, Hill BT. Gaffney KJ, et al. Among authors: sobecks r. J Oncol Pharm Pract. 2022 Jun 7:10781552221104422. doi: 10.1177/10781552221104422. Online ahead of print. J Oncol Pharm Pract. 2022. PMID: 35673764
Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience.
Sawalha Y, Hill BT, Rybicki LA, Sun D, Dean RM, Jagadeesh D, Hamilton BK, Gerds AT, Sobecks RM, Andresen S, Liu HK, Majhail NS, Pohlman B, Kalaycio ME, Bolwell BJ, Smith MR. Sawalha Y, et al. Among authors: sobecks rm. Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e95-e102. doi: 10.1016/j.clml.2017.11.002. Epub 2017 Dec 6. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29208403
The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis.
Mei M, Pillai R, Kim S, Estrada-Merly N, Afkhami M, Yang L, Meng Z, Abid MB, Aljurf M, Bacher U, Beitinjaneh A, Bredeson C, Cahn JY, Cerny J, Copelan E, Cutler C, DeFilipp Z, Diaz Perez MA, Farhadfar N, Freytes CO, Gadalla SM, Ganguly S, Gale RP, Gergis U, Grunwald MR, Hamilton BK, Hashmi S, Hildebrandt GC, Lazarus HM, Litzow M, Munker R, Murthy HS, Nathan S, Nishihori T, Patel SS, Rizzieri D, Seo S, Shah MV, Solh M, Verdonck LF, Vij R, Sobecks RM, Oran B, Scott BL, Saber W, Nakamura R. Mei M, et al. Among authors: sobecks rm. Haematologica. 2023 Jan 1;108(1):150-160. doi: 10.3324/haematol.2021.280203. Haematologica. 2023. PMID: 35443559 Free PMC article.
189 results